DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ea4190/positioning_and_ma) has announced the addition of the "Positioning And Market Potential Of Cms-024 (Ysl, Tyroserleutide) In Hepatic Cancer In China" report to their offering.
The report is a comprehensive analysis of the competitive landscape of Hepatic cancer drugs under development in China with an objective to figure out the market potential and positioning of China Medical System's lead drug candidate - CMS-024 (PhIII). China is the most important market for Hepatic cancer drugs as more than half of worldwide incidence of hepatic cancer occur in China.
CMS-024 is targeted in the early stage setting as an adjuvant treatment, where surgery and local ablation are the first line treatment options. Surgery is associated with a very high recurrence rate (35-65% within 5 years), and hence a number of drugs are being developed to address this potential unmet need. This 21 page presentation will provide a complete clinical profile of CMS-024, positioning of this tripeptide in current treatment paradigm of HCC in China, CMS-024 clinical profile vis--vis competition in adjuvant HCC setting and in the unresectable HCC setting and the market potential of CMS-024.
Drugs Mentioned:
- Iodine I 131 ethiodized oil
- Low dose thalidomide
- Thymopentin
- Nexavar
- Cytokine induced killer cell
- PI-88
- Sutent
- Brivanib
- ABT-869
Key Topics Covered:
- 1. Executive Summary
- 2. Drug Overview- CMS-024/YSL/Tyroserleutide
- 3. CMS-024 - Mechanistic Evidence of Role in Hepatic Cancer
- 4. Regulatory and Clinical development of CMS-024- Chronology of events
- 5. CMS-024 -Key Findings from Preclinical data
- 6. CMS-024- Results of reported PhI/II clinical study and key conclusion from the results
- 7. Ph III Clinical trial design of CMS-024 in detail - Do recent changes in trial design post discussion with SFDA are positive or negative?
- 8. Pipeline drugs in development in adjuvant setting post surgery in HCC
- 9. CMS-024, how it stands against Nexavar in unresectable HCC?
- 10. Hepatic Caner- Potential Market in China
- 11. Conclusion
Companies Mentioned:
- China Medical System
- Bayer
- Bristol Myers Squibb
- Abbott
- Progen Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/ea4190/positioning_and_ma